News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Yempo Solutions runs 2026 roadshow to help Australian SMEs scale operations safely through outsourcing News Pushpay Debuts a Rebuilt Groups Experience, Kicking Off Its Most Ambitious Platform Overhaul to Date News Serving More Than One Million Developers, Syncfusion Celebrates 25th Anniversary News Real Intent Meridian CDC with Microarchitectural Analysis (MA) Transforms Clock Domain Crossing Sign-Off News Cyndra AI Launches Platform for Businesses to Deploy AI Employees Across Real Operations News HiBob Named 2026 HR Pacesetter Award Winner for Pioneering the AI-Era Operating Model